Entia

Entia is a London‑based medtech company that builds at‑home blood testing and remote monitoring solutions for oncology care, most notably the Entia Liberty full blood count analyser and associated virtual‑oncology services designed to reduce hospital visits and detect treatment toxicity earlier[3][1]. Entia’s product suite targets cancer patients, clinicians and life‑science partners by enabling haematological monitoring at home and feeding data and alerts into clinical workflows to prevent unplanned hospitalisations and personalise therapy[1][2].

High‑Level Overview

• Mission: Entia’s stated mission is to improve cancer care by making monitoring more accessible and personalised, enabling better quality of life and outcomes for patients undergoing systemic anti‑cancer therapies[3][2].
  - Investment/Support profile (when referenced by investors): Entia has raised growth capital from investors including BGF and Parkwalk to scale its Liberty product and commercial rollout[3][5].
  - Key sectors: MedTech, digital health/remote patient monitoring, virtual oncology and diagnostics (point‑of‑care/full blood count testing)[1][3].
  - Impact on the startup/healthcare ecosystem: Entia’s at‑home testing model advances the hospital‑at‑home and virtual oncology trend by reducing reliance on clinic‑based blood draws, supporting NHS adoption during COVID pilots, and enabling decentralized trials and life‑science partnerships that capture real‑world haematology data[3][1][4].

Origin Story

• Founding year & founder background: Entia was founded in 2015 by Dr Toby Basey‑Fisher after observing family members’ difficulties with poorly personalised cancer therapy; Dr Basey‑Fisher holds a PhD in Biomedical Physics from Imperial College London and an honorary lectureship there[3].
  - How the idea emerged: The concept grew from clinical collaborations at Imperial and first‑hand exposure to cancer care challenges, aiming to bring blood testing into patients’ homes to lessen treatment burden and better monitor toxicity[3].
  - Early traction / pivotal moments: Entia spent roughly four years in pilots, trials and development, supported NHS centres with RPM during COVID, completed multiple major trials evaluating Liberty across NHS sites, and secured backing from BGF and Parkwalk to support commercial roll‑out[3][4][5].

Core Differentiators

• Product differentiators: Entia combines a point‑of‑care full blood count analyser (Liberty) designed for home use with analytics and clinical workflows tailored to oncology monitoring, distinguishing it from purely telehealth platforms[3][1].
  - Developer / clinical experience: The product is built for integration into clinical pathways and regulatory environments (GCP/compliant data management for trials), with reported rapid site onboarding and trial recruitment supported by digital data tooling[4].
  - Speed, pricing, ease of use: Entia emphasises at‑home convenience that reduces patient travel and clinic burden; published accounts highlight rapid recruitment and operational gains in multicentre studies versus manual processes, although public pricing details are not disclosed in the cited sources[4][1].
  - Community / partnership ecosystem: Entia has partnered with NHS centres and life‑science companies and received strategic investment from European funds, enabling trials and commercial pilots within UK health systems[3][5].

Role in the Broader Tech Landscape

• Trend alignment: Entia rides the hospital‑at‑home, remote patient monitoring and decentralised clinical trials trends that accelerate care outside hospitals and capture longitudinal real‑world data[1][4].
  - Why timing matters: Increased NHS openness to remote care during COVID, regulatory pathways for point‑of‑care diagnostics, and payer/health‑system pressure to reduce unplanned admissions create a favorable backdrop for home blood testing solutions[3][1].
  - Market forces in their favor: Rising oncology patient volumes, demand to personalise systemic therapy, and sponsors’ interest in decentralized trials support adoption of home monitoring and devices that provide reliable clinical-grade blood results[1][4].
  - Influence on ecosystem: By operationalising home blood testing at scale and integrating with clinical and trial workflows, Entia lowers friction for virtual oncology programs and creates a data stream that can inform treatments and life‑science research[3][4].

Quick Take & Future Outlook

• What’s next: Entia is focused on scaling Liberty’s commercial rollout in the UK (and internationally via trials), deepening NHS and life‑science partnerships, and leveraging investment to move from pilots to broader clinical adoption[3][5].
  - Trends that will shape its journey: Wider acceptance of hospital‑at‑home care, reimbursement models for remote diagnostics, and continued decentralisation of clinical trials will drive demand for Entia’s offering[1][4].
  - How influence might evolve: If Entia demonstrates robust clinical outcomes and cost benefits at scale, it could become a standard component of virtual oncology pathways and a data partner for drug safety monitoring and personalised dosing—shifting routine haematology surveillance from clinics into homes[3][1].

Quick take: Entia addresses a concrete pain point—routine blood monitoring for cancer patients—by combining a home‑usable full blood count device with clinical workflows and trials experience; continued regulatory, payer and health‑system validation will determine whether it transitions from promising pilot partner to mainstream virtual‑oncology infrastructure[3][1][4].